• PRAMOD SHANKPAL Additional Professor, Department of Pharmacology, Topiwala National Medical College and BYL Nair Charitable Hospital
  • SHWETA SURVE Speciality Medical Officer, Department of Pharmacology, Lokmanya Tilak Municipal Medical College and General Hospital Sion


Objective: The present study was undertaken to evaluate the acute and chronic anxiolytic effects of nifedipine in comparison to diazepam using in Swiss Albino mice using two behavioral models.

Methods: 30 Swiss albino mice were divided into 5 groups with 6 mice in each group. The study was conducted in two phases to evaluate acute and chronic effects. The groups consisted of diazepam (1 mg/kg), 3 doses of nifedipine (2.6 mg/kg, 5.2 mg/kg and 10.4 mg/kg) and vehicle control. The Elevated Plus Maze (EPM) and Light and Dark box were used to evaluate the anti-anxiety effects. The number of entries and time spent in the open arm of the elevated plus-maze and in the light area of light and dark box model were noted and compared among the 5 groups. Observations were analyzed using ANOVA and post hoc Tukey's test.

Results: Nifedipine (5.2 mg/kg and 10.4 mg/kg) significantly increased the number of entries and time spent in the open arm compared to vehicle control in the EPM test (p<0.001). Similarly, in the light and dark box test, nifedipine (5.2 mg/kg and 10.4 mg/kg) increased the number of entries and time spent in the light area compared to vehicle control (p<0.05). However, the low dose of nifedipine (2.6 mg/kg) did not exhibit significant findings.

Conclusion: Two doses of nifedipine (5.2 mg/kg and 10.4 mg/kg) possess anti-anxiety effects both on acute and chronic administration in both elevated plus maze and light and dark box model.

Keywords: Anxiolytic, Dihydropyridines, Behavioural model, Mice


Download data is not yet available.


1. Jyothsna VC, Balaji O, Chogtu B. Effect of different statins in animal model of anxiety in wistar rats. Asian J Pharm Clin Res 2018;11:369-71.
2. Olatunji BO, Cisler JM, Tolin DF. Quality of life in anxiety disorders: a meta-analytic review. Clin Psychol Rev 2007;27:572-81.
3. Shri R. Anxiety: causes and management. Int J Behav Sci 2010;5:100-18.
4. Manavi C, Rajkumar V, Vijai L. Anxiolytic effects of Plumeria rubra var. acutifolia (Poiret) L. flower extracts in the elevated plus-maze model of anxiety in mice. Asian J Psychiat 2013;6:113–8.
5. Mahendra P, Bisht S. Anti-anxiety activity of Coriandrum sativum assessed using different experimental anxiety models. Indian J Pharmacol 2011;43:574-7.
6. Soodan S, Arya A. Understanding the pathophysiology and management of anxiety disorders. Int J Pharm Pharm Res 2015;4:251-78.
7. Catterall WA. Voltage-gated calcium channels. Cold Spring Harbor Perspect Biol 2011;3:1-23.
8. Elliott WJ, Ram CV. Calcium channel blockers. J Clin Hypertens 2011;13:687-9.
9. Larkin JG, Thompson GG, Scobie G, Forrest G, Drennan JE, Brodie MJ. Dihydropyridine calcium antagonists in mice: blood and brain pharmacokinetics and efficacy against pentylenetetrazol seizures. Epilepsia 1992;33:760-9.
10. El Ganouni S, Tazi A, Hakkou F. Potential serotonergic interactions with the anxiolytic-like effects of calcium channel antagonists. Pharmacol Biochem Behav 1998;60:365-9.
11. Umukoro S, Ashorobi RB, Essein EE. Anticonvulsant and anxiolytic effects of calcium channel blockers in mice. J Med Sci 2006;6:1021-4.
12. Tanwani H, Nyati P, Atal S, Churihar R. Evaluation of antianxiety, antidepressant and sedative effects of nimodipine in swiss albino mice. Int J Pharm Pharm Sci 2016;8:260-3.
13. Goodman L, Gilman A, Brunton L, Hilal Dandan R, Knollmann B. Goodman and Gilman's the pharmacological basis of therapeutics. 13th ed. New York: McGraw-Hill Education; 2018.
14. Sreedharan N, Rao PG, Rau NR, Shankar PR. Antihypertensive prescribing preferences in three South Indian Hospitals: cost analysis, physicians' perspectives and emerging trends. Int J Clin Pharmacol Ther 2011;49:277.
15. Gupta R, Malhotra A, Malhotra P. Study of prescribing pattern of drugs used in the treatment of hypertension in a tertiary care teaching hospital in North India: an observational study. Int J Res Med Sci 2018;6:2380.
16. Sweetman SC. Martindale: the complete drug reference. 36th Edition. London: Pharmaceutical Press: Cardiovascular drugs; 2009.
17. Nishino T, Takeuchi T, Takechi K, Kamei C. Evaluation of anxiolytic-like effects of some short-acting benzodiazepine hypnotics in mice. J Pharmacol Sci 2008;107:349-54.
18. Walf AA, Frye CA. The use of the elevated plus maze as an assay of anxiety-related behavior in rodents. Nat Protoc 2007;2:322-8.
19. Veena RI, Kiranmai G, RAVI PP. Pharmacological evaluation of the antianxiety activity of Desmostachya bipinnata leaves in animal models. Int J Curr Pharm Res 2017;9:152-4.
20. Bourin M, Hascoët M. The mouse light/dark box test. Eur J Pharmacol 2003;463:55-65.
21. Moser DK. The rust of life: impact of anxiety on cardiac patients. Am J Crit Care 2007;16:361-9.
22. Uchida S, Yamada S, Nagai K, Deguchi Y, Kimura R. Brain pharmacokinetics and in vivo receptor binding of 1, 4-dihydropyridine calcium channel antagonists. Life Sci 1997;61:2083-90.
23. Ninan PT. The functional anatomy, neurochemistry, and pharmacology of anxiety. J Clin Psychiatry 1999;60 Suppl 22:12-7.
24. Cortes R, Supavilai P, Karobath M, Palacios JM. Calcium antagonist binding sites in the rat brain: quantitative autoradiographic mapping using the 1, 4-dihydropyridines [3 H] PN 200-110 and [3 H] PY 108-068. J Neural Transm 1984;60:169-97.
25. Feder A, Costi S, Iacoviello B, Murrough J, Charney D. Anxiety disorders: neurobiology and neuroscience. In: B Sadock, V Sadock, P Ruiz, ed. Kaplan and sadock's comprehensive textbook of psychiatry. 10th ed. Philadelphia: Wolters Kluwer Health/lippincott Williams and Wilkins; 2017.
26. Pan Y, Cai W, Cheng Q, Dong W, An T, Yan J. Association between anxiety and hypertension: a systematic review and meta-analysis of epidemiological studies. Neuropsychiatr Dis Treat 2015;11:1121.
257 Views | 352 Downloads
How to Cite
SHANKPAL, P., and S. SURVE. “EVALUATION OF ANTI-ANXIETY EFFECT OF NIFEDIPINE COMPARED TO DIAZEPAM IN SWISS ALBINO MICE USING BEHAVIOURAL MODELS”. International Journal of Pharmacy and Pharmaceutical Sciences, Vol. 12, no. 5, May 2020, pp. 6-9, doi:10.22159/ijpps.2020v12i5.37211.
Original Article(s)